Search research articles
Contact Us
Filters
Showing results (1-10 of 122) with videos related to
Page
of 13
Sort By:
Mens Sana Monographs
|
October 21, 2011
Medical guidelines and performance measures: the need to keep them free of industry influence
Peter Q Eichacker, Charles Natanson
Intensive Care Medicine
|
February 28, 2007
Increasing evidence that the risks of rhAPC may outweigh its benefits
Peter Q Eichacker, Charles Natanson
Critical Care Medicine
|
January 25, 2003
Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials
Peter Q Eichacker, Charles Natanson
Intensive Care Medicine
|
August 25, 2010
Evaluating guidelines for critical care: a need for detail
Peter Q Eichacker, Charles Natanson
Annals of Internal Medicine
|
August 18, 2015
ACP Journal Club: in early septic shock, early goal-directed therapy did not reduce 90-day mortality
Dharmvir S Jaswal, Peter Q Eichacker
Critical Care Medicine
|
September 28, 2002
Prophylactic granulocyte colony-stimulating factor in the critically ill: carefully balancing the benefits and risks
Zenaide M N Quezado, Peter Q Eichacker
Critical Care Medicine
|
November 29, 2007
Separating practice guidelines from pharmaceutical marketing
Peter Q Eichacker, Charles Natanson, Robert L Danner
Critical Care Medicine
|
December 30, 2008
Recombinant human activated protein C, package labeling, and hemorrhage risks
Daniel A Sweeney, Charles Natanson, Peter Q Eichacker
Critical Care Medicine
|
March 25, 2020
Sepsis Bundles That Focus on Clinician Judgment and Proven Interventions Are Needed to Increase Bundle Compliance and Effectiveness
Jeffrey R Strich, Jeffrey Wang, Peter Q Eichacker
Current Infectious Disease Reports
|
August 31, 2013
The Surviving Sepsis Campaign's Revised Sepsis Bundles
Amisha V Barochia, Xizhong Cui, Peter Q Eichacker
Page
of 13
Search research articles
Search
Showing results (1-10 of 122) with videos related to
Sort By:
Page
of 13
Mens Sana Monographs
|
October 21, 2011
Medical guidelines and performance measures: the need to keep them free of industry influence
Peter Q Eichacker, Charles Natanson
Intensive Care Medicine
|
February 28, 2007
Increasing evidence that the risks of rhAPC may outweigh its benefits
Peter Q Eichacker, Charles Natanson
Critical Care Medicine
|
January 25, 2003
Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials
Peter Q Eichacker, Charles Natanson
Intensive Care Medicine
|
August 25, 2010
Evaluating guidelines for critical care: a need for detail
Peter Q Eichacker, Charles Natanson
Annals of Internal Medicine
|
August 18, 2015
ACP Journal Club: in early septic shock, early goal-directed therapy did not reduce 90-day mortality
Dharmvir S Jaswal, Peter Q Eichacker
Critical Care Medicine
|
September 28, 2002
Prophylactic granulocyte colony-stimulating factor in the critically ill: carefully balancing the benefits and risks
Zenaide M N Quezado, Peter Q Eichacker
Critical Care Medicine
|
November 29, 2007
Separating practice guidelines from pharmaceutical marketing
Peter Q Eichacker, Charles Natanson, Robert L Danner
Critical Care Medicine
|
December 30, 2008
Recombinant human activated protein C, package labeling, and hemorrhage risks
Daniel A Sweeney, Charles Natanson, Peter Q Eichacker
Critical Care Medicine
|
March 25, 2020
Sepsis Bundles That Focus on Clinician Judgment and Proven Interventions Are Needed to Increase Bundle Compliance and Effectiveness
Jeffrey R Strich, Jeffrey Wang, Peter Q Eichacker
Current Infectious Disease Reports
|
August 31, 2013
The Surviving Sepsis Campaign's Revised Sepsis Bundles
Amisha V Barochia, Xizhong Cui, Peter Q Eichacker
Page
of 13